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PTVadapt was generated by adding a margin of 5 mm to the 
residual tumour visible on the intermediate MRI images 
(GTVadapt). A simultaneous integrated boost of 3.0 Gy/fr 
was delivered to PTVadapt on the last 6 frs of RT until a total 
dose of 45.6 Gy in 18 frs. 
 
Results: From September 2009 to September 2015, 56 pts 
completed the preoperative treatment. Toxicity. No G4 
toxicity occurred. G3 toxicity was only gastrointestinal: 
diarrhoea in 9/56 pts (16%), and proctitis in 3/56 (5%). 
Diarrhoea started before the adaptive RT phase in all the 
cases. Treatment feasibility. Two pts interrupted 
radiotherapy after 7 and 13 fractions, respectively, the 
remaining pts (54/56=96%) completed the treatment; the 
median duration of RT was 25 days (22-36 days). 47/56 pts 
(84%) and 45/56 pts (80%) received the full dose of 
oxaliplatin and 5-FU, respectively: 18% of pts received 
moderately reduced doses (60%-90%), and only two pts (2%) 
received less than 60% of the planned dose. Responses. Two 
pts achieved clinical complete response (cCR) and refused 
surgery, 1 pt was lost, 1 pt had early distant progression. 
Fifty-two pts underwent surgery (49 R0, 3 R1). Fifteen pts 
(29%) had pathological complete response (pCR); 24/52 (46%) 
had Tumor Regression Grade 3 response: 14/52 (27%) and 
6/52 (12%) had ≤5%, and 6 -10% residual viable cells, 
respectively. Regarding the two patients with cCR who 
refused surgery, 1 pt is still in cCR after 69 months, 1 pt had 
local relapse and underwent transanal resection 1 year after 
the preoperative treatment. 
 
Conclusion: This study confirms that adaptive Radiotherapy 
with Tomotherapy concomitant with oxaliplatin based 
chemotherapy in the preoperative treatment of rectal cancer 
is feasible, has an acceptable G3 toxicity rate and a very 
encouraging tumour response rate. A further dose escalation 
to the PTVadapt could be feasible and could increase the pCR 
and/or cCR rates. 
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Purpose or Objective: To evaluate the contribution of 
components for intense multimodal local treatment to the 
most adverse loco-regional staging scenario of M0 rectal 
cancer. 
 
Material and Methods: From 1/00 to 12/13, 95 cT4NXM0 
patients were treated with radical intent. 54 completed 
preoperative intensified chemo-radiation (all had post-
resection intraoperative electron pelvic boost, IOERT). 
Adjuvant systemic chemotherapy was recommended 
considering individualized risk features. Incomplete and 
complete pre and intra-operative treatment cohorts were 
comparable in characteristics: male (44/55%); age >70 
(44/33%); PS 0 (46/62%); inferior segment (42/41%); grade 2 
(67/62%); cN+ (75/83%). 
 
Results: With a median follow-up time of 62 months overall, 
disease-free (DFS) and loco-regional relapse-free survival 
were superior in the cohort of complete intensification (75% 
vs 51%, p=0.009; 67% vs 54%, p=0.03; 77% vs 71%, p=0.01), 
respectively. IOERT significantly improved presacral control 
rates. Multivariate analysis indicated that uninvolved surgical 
margin and intense tumour regression grade assessed 
response, were protective for DFS. 
 
Conclusion: Multimodal preoperative approach contributed 
to remarkable cancer-control outcomes and survival in cT4M0 
rectal patients, if components of therapy are feasible to be 
maximized (including free surgical margins) and an intense 
pathological disease response is described. 
 
EP-1302  
The utility of Squamous Cell Carcinoma SCCAg as a marker 
for treatment response or relapse 
L. Pietrzak
1The Maria Sklodowska-Curie Memorial Cancer Center, 
Radiotherapy, Warsaw, Poland 
1, K. Bujko1 
 
Purpose or Objective: The utility of SCCAg as a marker for 
treatment response or relapse is unknown in anal cancer. 
 
Material and Methods: This is a retrospective analysis of 28 
patients in whom SCCAg serum level was increased prior to 
treatment (mean 6,4 ng/ml, range 1,6-19,6 ng/ml). In all 
patients, measurement of SCCAg was performed at baseline, 
after completion of chemoradiation and at each visit during 
follow-up (median 35 months, range 7-81). All patients were 
treated radically. 
 
Results: In 27 (96%) patients SCCAg level decreased to normal 
level after treatment. One remaining patient had persistent 
unreseceble tumor confirmed by pathology and persistent 
high SCCAg level. Only one of 27 patients with normalization 
of SCCAg after chemoradiation had persistent ulceration in 
the anal canal and persistent enlarger inguinal lymph node. 
This patient underwent abdominoperineal resection with 
inguinal lymphadenectomy. On pathological examination only 
a few cancer cells were found in the inguinal nodes and the 
primary tumour site was free of cancer.. In six patients, 
increase of SCCAg was observed during follow-up. In one of 
these 6 patients, locoregional recurrence was also detected 
clinically at the same time. In 4 patients, the diagnostic 
examinations performed because of elevated SCCAg reveled 
locoregional recurrence (n=2) or distant metastases (n=2). In 
one remaining patient the diagnostic examinations were 
negative; distant metastases were detected 5 months 
thereafter. The remaining 20 patients had both: sustained 
clinical complete regression and normal SCCAg level.  
 
Conclusion: This study suggests utility of SCCAg in the 
monitoring of response to chemoradiation and in the 
detection of recurrence 
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Purpose or Objective: Preoperative radiotherapy (RT), alone 
or in combination with chemotherapy (CT) is the standard of 
care in patients (pts) with locally advanced rectal cancer 
(LARC). Nevertheless in those tumors in which the down-
sizing and down-staging are necessary, (cT3 MRF - / + N0 of 
lower rectum or cT3-4 MRF + / N0-2) preoperative chemo-
radiotherapy (CT-RT) is recommended. There is a correlation 
between RT dose and response and the tumor regression 
grade (TRG) represents an independent prognostic factor. 
The aim of the study is to analyze the role of RT dose 
intensification in the preoperative treatment of LARC in 
terms of feasibility, toxicity and pathological response grade. 
 
Material and Methods: We have retrospectively analyzed 69 
pts with histological diagnosis of LARC (stage II-III) treated in 
five Italian Radiotherapy centres. The treatment programme 
included: intensity-modulated radiotherapy (IMRT) delivered 
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to total mesorectum and pelvic lymphatic drainage with 
simultaneous integrated boost (SIB) to the tumor bed and 
adjacent mesorectum. Fluoropirimidine-based CT was 
administered. The acute toxicity was evaluated according to 
CTCAE 4.0 scale. 
 
Results: Pts characteristics: median age 63.5yy (range 29-
84), median tumor distance-IAS 50 mm (range 0-100), median 
tumor size 50 mm (range 25-120), MRF involvement 24 pts, 
Stage IIA 7 pts – III 62 pts. All of the pts completed the RT; 45 
Gy were delivered to total mesorectum and lymphatic 
drainage with median SIB dose of 55 Gy (range 52.5-57.5). 
Forty-nine (71%) pts received concomitant CT with 
capecitabine alone and 17 (25%) capecitabine plus 
oxaliplatin. Globally, 16/69 (23%) pts did not complete CT for 
haematological (5) or, gastrointestinal toxicities (5) and 
other causes (6). Fourteen (20%), 33 (48%) and 23 (33%) pts 
experienced grade 1-2 haematological, gastrointestinal and 
genitourinary toxicity, respectively. Two out of 69 (3%) pts 
developed grade 3 haematological toxicity and 9/69 (13%) 
grade 3 gastrointestinal toxicity. Forty-three pts underwent 
surgery (LAR 28, APR 10, local excision 5 pts) but definitive 
histology is not yet available in 7 pts. Twenty-six pts are 
waiting for surgery. The tumor downstaging was documented 
in 29/36 (80.5%) pts. Forty-four rate (16/36) of surgical cases 
achieved pathologic complete response. 
 
Conclusion: Despite the limitations related to the 
heterogeneity of the treatment delivery (SIB dose and 
concomitant CT), the RT dose-escalation in the preoperative 
treatment of LARC seems feasible, well tolerated and 
effective in terms of tumor downstaging and pathological 
complete response. Nevertheless, this results need to be 
confirmed on a larger cohort. 
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Purpose or Objective: To report the results of a 
retrospective pooled analysis of anal carcinoma (AC) patients 
treated with IMRT, VMAT, helical tomotherapy (HT) and daily 
image-guided RT (IGRT) in 3 Swiss radiotherapy centers. 
 
Material and Methods: Local control (LC) and grade 3 or 
more toxicity rate (CTCAE v.4.0) were the primary endpoints. 
Overall (OS), disease-free (DFS), distant metastasis-free 
(DMFS) and colostomy-free survival (CFS) were also studied. 
Volumes were defined as follows: CTV1 : Anal canal, 
mesorectal, pelvic, and inguinal nodes. CTV2 : anal tumor 
and clinically positive nodes. Planning target volumes were 
obtained by adding 5-mm margin to the CTV (PTV1 and PTV2, 
respectively). PTV1 received 36 Gy (1.8 Gy/fraction) 
delivered with IMRT (n = 44), VMAT (n = 16) or HT (n = 100), 
while PTV2 received a sequential boost up to a total dose of 
59.4-60 Gy (1.8-2 Gy/fr), delivered with IMRT (n = 16), VMAT 
(n = 18) , HT (n = 59) or 3D-conformal RT (CRT, n = 67). 
 
Results: From 03.2006 to 04.2015, 160 patients were treated; 
30, 68, 60 and 2 patients presented stage I, II, III, and IV, 
respectively. Median age was 62 years (range: 35-89). A 
planned gap was used in 130 patients. Median gap duration 
was 10 days (range, 5-24). Concomitant chemotherapy (CTX) 
was delivered in 149 patients, mainly using mitomycine C 
combined with fluoropyrimidines (i.v. or oral, n = 139). 
Median follow-up was 45 months (range: 3-97). Four-year LC, 
OS, DFS, DMFS and CFS rates were 83.6%, 82.3%, 82.7%, 93.4% 
and 88%, respectively. Time to progression for relapsing 
patients was 29 months (range: 1-78). A total of 24 patients 
presented a recurrence (local only in 14, locoregional in 1, 
locoregional and distant in 1, local and distant in 3, regional 
only in 2, and distant only in 3 patients). Fourteen patients 
underwent a colostomy because of local recurrence (n = 12) 
or pretreatment anal sphincter dysfunction (n = 2). Grade 3 
acute toxicity was observed in 30 patients (18.4%), usually as 
erythema (23/30) or diarrhoea (10/30). No late G3 cutaneous 
toxicity was recorded. At the time of analysis, 150 patients 
presented more than 6 months of follow-up and were 
considered evaluable for late toxicity. Data about late 
toxicity were not available for 6 patients, followed in other 
Institutions. Looking at the final 144 patients, 3 of them 
patients presented a late G3 gastrointestinal toxicity (anal 
incontinence). No G4 acute or late toxicity was recorded. No 
significant differences were observed in terms of local 
control or acute G3 toxicity between IMRT and 3D-CRT boost 
techniques.  
 
Conclusion: A total dose of 59.4/60 Gy to the anal tumor and 
involved nodes, including 36 Gy to the elective nodal regions 
, is effective and safe when delivered using modern IMRT 
techniques and daily IGRT. Thus, VMAT or HT and concurrent 
CTX are the standard of care in our institutions. 
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Purpose or Objective: The aim of the study was to analyze if 
time from neo-adjuvant chemoradiotherapy (CTRT) to radical 
surgery influences oncologic outcomes in locally advanced 
rectal cancer.  
 
Material and Methods: We performed a retrospective 
analysis of 132 consecutive patients with rectal cancer 
treated at our Institute from March 2006 to March 2013 who 
underwent to neoadjuvant therapy followed by radical 
resection. Of these, 12 patients were excluded as lost at 
follow up, 3 patients for peritoneal carcinosis detection at 
surgery time and 3 patients refused surgery after 
neoadjuvant treatment. The remaining patients were 
analyzed and divided into two groups according to time to 
surgery (group A ≤ 8 weeks and group B > 8 weeks) after 
completion of CTR 
 
Results: A total of 114 patients underwent total mesorectal 
excision (TME) after neoadjuvant treatment for stage II and 
III rectal cancer between 0 and 15 cm from anal verge. There 
were 51 (45%) patients in group A (interval ≤ 8 weeks) and 63 
(55%) in group B (interval > 8 weeks). Median time from 
chemo-radiotherapy and surgery was 7 weeks (range 1-8) and 
12 weeks ( range 9-17), respectively, in group A and B. In 
group B there was a major number of patients with no 
involvement of circumferential resection margin (CRM), 60 vs 
48, and a higher number of major pathologic responce (pT0 – 
pT1), 19 vs 9. Disease free survival (DFS) at 5 years was 85.7% 
vs 75.9% and overall survival (OS) at 5 years was 83.7% vs 92% 
in group A vs group B. 
 
Conclusion: In our analysis we did not reach statistical 
significance difference as regards DFS and OS in the two 
groups of patients; however we observed a favorable trend in 
the group of patients that underwent to surgery after 8 
weeks from neoadjuvant treatment in terms of pathological 
responce and free radial margin. 
 
 
